AstraZeneca PLC (AZN) operating KPIs
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca u.S. GTN rebates, chargebacks & credits settled / paid in year ($M) ($M)
Form 20-F Note 2 — U.S. GTN Accrual Rollforward
Latest, FY2025
22,479
Period ended Dec 31, 2025
Change on a year earlier
+20.1%
18,710 in FY2024
History
3 years
Since FY2023
Sources
1
Form 20-F FY2025 Annual Report
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | U.S. GTN rebates, chargebacks & credits settled / paid in year ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 22,479 | +20.1% | Form 20-F FY2025 Annual Report ↗ |
| FY2024 | Dec 31, 2024 | 18,710 | +9.3% | Form 20-F FY2025 Annual Report ↗ |
| FY2023 | Dec 31, 2023 | 17,112 | – | Form 20-F FY2025 Annual Report ↗ |
Breakdown
What makes up u.s. gtn rebates, chargebacks & credits settled / paid in year ($m)
- U.S. Managed Care & Medicare rebates settled ($M)13,381 · FY2025
- U.S. Chargebacks settled ($M)4,568 · FY2025
- U.S. Medicaid rebates settled ($M)2,472 · FY2025
- U.S. Cash discounts settled ($M)480 · FY2025
- U.S. Customer returns settled ($M)135 · FY2025
- U.S. Branded Prescription Drug fee settled ($M)124 · FY2025
- U.S. Other GTN deductions settled ($M)1,319 · FY2025
Cite this data
StockData. (2026). AstraZeneca U.S. GTN rebates, chargebacks & credits settled / paid in year ($M) ($M), annual FY2023–FY2025 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/us_gtn_paid_total
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.